THAR vs. SEEL, NEXI, KZIA, GNPX, CPHI, DRUG, LIPO, CLVR, SNPX, and GTBP
Should you be buying Tharimmune stock or one of its competitors? The main competitors of Tharimmune include Seelos Therapeutics (SEEL), NexImmune (NEXI), Kazia Therapeutics (KZIA), Genprex (GNPX), China Pharma (CPHI), Bright Minds Biosciences (DRUG), Lipella Pharmaceuticals (LIPO), Clever Leaves (CLVR), Synaptogenix (SNPX), and GT Biopharma (GTBP). These companies are all part of the "pharmaceutical preparations" industry.
Tharimmune (NASDAQ:THAR) and Seelos Therapeutics (NASDAQ:SEEL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, community ranking, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.
Tharimmune has a net margin of 0.00% compared to Seelos Therapeutics' net margin of -1,373.61%. Seelos Therapeutics' return on equity of 0.00% beat Tharimmune's return on equity.
1.2% of Tharimmune shares are held by institutional investors. Comparatively, 23.4% of Seelos Therapeutics shares are held by institutional investors. 2.4% of Tharimmune shares are held by company insiders. Comparatively, 5.4% of Seelos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Tharimmune has higher earnings, but lower revenue than Seelos Therapeutics.
In the previous week, Seelos Therapeutics had 4 more articles in the media than Tharimmune. MarketBeat recorded 7 mentions for Seelos Therapeutics and 3 mentions for Tharimmune. Tharimmune's average media sentiment score of 1.45 beat Seelos Therapeutics' score of 0.13 indicating that Tharimmune is being referred to more favorably in the media.
Seelos Therapeutics received 71 more outperform votes than Tharimmune when rated by MarketBeat users.
Seelos Therapeutics has a consensus target price of $360.00, suggesting a potential upside of 15,284.62%. Given Seelos Therapeutics' higher possible upside, analysts clearly believe Seelos Therapeutics is more favorable than Tharimmune.
Tharimmune has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500. Comparatively, Seelos Therapeutics has a beta of 2.03, indicating that its share price is 103% more volatile than the S&P 500.
Summary
Seelos Therapeutics beats Tharimmune on 9 of the 13 factors compared between the two stocks.
Get Tharimmune News Delivered to You Automatically
Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding THAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tharimmune Competitors List
Related Companies and Tools
